Compare Petróleo Brasileiro SA (PBR) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Stryker Corporation — how do they compare? Petróleo Brasileiro SA trades at $25.36 (market cap $151.94B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Petróleo Brasileiro SA is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Stryker Corporation for 21 Days on average.
| PBR | SYK | |
|---|---|---|
Market Cap | $151.94B | $106.24B |
Volume | 30,240,092 | 2,982,001 |
Sector | Energy | Health |
52-Week High | $24.69 | $388.35 |
52-Week Low | $11.54 | $269.75 |
Typical Hold Time | 25 Days | 21 Days |
Enterprise Value | $212.36B | $117.70B |
Dividend Yield | 6.79% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.41, up 5.92% in 24 hours, reflecting strong momentum. The stock shows robust fundamentals with a P/E of 6.24 and net income margin of 24.52%, supported by recent earnings beats. Technical indicators signal a bullish trend, though RSI levels suggest potential overbought conditions. Positive news includes a new oil discovery off Amapa and a 22-year LNG deal with Cheniere Energy, highlighting growth prospects.
The outlook for PBR is favorable due to solid profitability, expansion projects, and analyst consensus leaning buy. Key risks involve political interference in Brazil, volatile oil prices, and high debt levels. Investors should weigh strong cash flows against geopolitical and commodity cycle exposures for balanced decision-making.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
